Checkpoint Therapeutics presents updated cosibelimab lung cancer results

Checkpoint Therapeutics announced updated interim results from the ongoing global, open-label, multicohort Phase 1 clinical trial of its anti-PD-L1 antibody, cosibelimab, in patients with advanced cancers, including a cohort of patients with previously untreated high PD-L1 expressing advanced non-small cell lung cancer. The updated interim results are being presented in a poster presentation at the Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting being held virtually from November 9-14, 2020. Summary of NSCLC Data Presented at SITC: The ongoing trial is evaluating cosibelimab administered as a fixed dose of 800 mg every two weeks or 1200 mg every three weeks. The NSCLC cohort includes patients with Stage IV NSCLC with high PD-L1 tumor expression as determined by immunohistochemistry, with no prior systemic treatment for advanced/metastatic NSCLC and no epidermal growth factor receptor activating mutation or anaplastic lymphoma kinase translocation. As of the interim analysis, 25 patients with NSCLC were enrolled and evaluable for efficacy by investigator assessment with at least one post-baseline tumor assessment or discontinued treatment prior. At the time of analysis, 123 patients with advanced cancers had been treated with cosibelimab and were evaluable for safety. Cosibelimab appeared to be safe and well-tolerated with a potentially favorable safety profile as compared to anti-PD-1 therapies currently available. The most common treatment-related adverse events included fatigue and rash, with only 2 patients discontinuing treatment due to a TRAE. Grade greater than or equal to3 TRAEs occurred in only 6 patients, most commonly anemia and fatigue.